These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rituximab therapy in necrotizing autoimmune myopathy associated with anti-SRP antibody: A clinical case review.
    Author: Nóvoa Medina FJ, Gutiérrez Martínez J, González González Y, Romero Díaz B, Machín García S, Rosas Romero A.
    Journal: Reumatol Clin (Engl Ed); 2018; 14(6):379-381. PubMed ID: 28389200.
    Abstract:
    Necrotizing autoimmune myopathy (NAM) is a rare and emerging entity of idiopathic inflammatory myopathy (IIM). They have been associated with connective tissue disorders, viral infections, malignancy, anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase protein (with or without the use of statins). Anti-SRP associated NAM has different clinical and histological characteristics that differentiate them from other IIM, resulting in a poor prognosis. Very few cases treated with rituximab have been published, with varying clinical response. Here we describe a case of anti-SRP associated NAM refractory to conventional immunosuppressants and its successful long-term management with the combination of rituximab, corticosteroids and methotrexate.
    [Abstract] [Full Text] [Related] [New Search]